Vogenx Unveils Terms for Planned Nasdaq Offering
Clinical-stage biotechnology company Vogenx has announced the terms of its proposed initial public offering, seeking to raise approximately $75 million as it advances its pipeline of treatments for endocrine and metabolic disorders.
The Raleigh, North Carolina-based company plans to offer 6.3 million shares at a price range of $11 to $13 per share. At the midpoint of the proposed pricing, Vogenx would achieve a fully diluted market valuation of approximately $173 million.
The company intends to list its common stock on the Nasdaq Global Market under the ticker symbol VOGX, with JonesTrading serving as the sole bookrunner for the offering.
Focused on High-Need Metabolic Disorders
Vogenx is a clinical-stage biopharmaceutical company developing therapies targeting diseases caused by metabolic dysfunction. Its research focuses on conditions with limited treatment options, including post-bariatric hypoglycemia (PBH), gastroparesis, and other endocrine disorders.
The company’s strategy centers on developing orally administered therapies designed to improve glucose regulation and metabolic function while addressing significant unmet medical needs.
Lead Drug Candidate Advances Through Mid-Stage Trials
Vogenx’s most advanced product candidate is mizagliflozin, an orally administered, minimally absorbed sodium-glucose transporter 1 (SGLT1) inhibitor. The company holds worldwide commercialization rights for the drug outside of Japan, South Korea, and Taiwan through a licensing agreement with Kissei Pharmaceutical.
To date, mizagliflozin has been administered to more than 500 participants across 10 clinical studies, including two completed Phase 2 trials involving patients with post-bariatric hypoglycemia.
The drug is currently being evaluated in the company’s ongoing Phase 2b EMERGE trial, which aims to further assess its safety and efficacy for PBH. Beyond this indication, Vogenx is also investigating mizagliflozin as a potential treatment for gastroparesis and GIP-dependent Cushing’s Syndrome.
Pipeline Extends Beyond Lead Program
In addition to mizagliflozin, Vogenx is developing VGX-2857, a preclinical small-molecule candidate targeting broader metabolic disease indications.
The company believes the program could eventually support therapies focused on long-term metabolic management, including weight maintenance, expanding its presence within the rapidly growing metabolic disease market.
IPO Proceeds to Support Clinical Development
Funds raised through the IPO are expected to support continued clinical development of mizagliflozin, advance additional pipeline programs, and provide working capital for general corporate purposes.
Founded in 2021, Vogenx has positioned itself as an emerging biotechnology company focused on developing innovative treatments for metabolic diseases that currently have limited therapeutic options.
Outlook
Vogenx enters the public markets as investor interest in metabolic disease therapies continues to grow, driven by expanding research into obesity, diabetes, gastrointestinal disorders, and related endocrine conditions. The success of its planned $75 million IPO will largely depend on investor confidence in the ongoing Phase 2b development of mizagliflozin and the company’s ability to demonstrate meaningful clinical progress across its broader pipeline.
